Friday, January 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

World Health Organisation’s Senior Advisor to Speak at 21st Annual Superbugs & Superdrugs Conference

by Global Biodefense Staff
December 2, 2018
The Up-Hill Battle of Antibiotic Resistance in the World of Infection Prevention

Hospital-Associated Methicillin-resistant Staphylococcus aureus (MRSA). The bacteria shown is strain MRSA252, a leading cause of hospital-associated infections in the U.S. and U.K. Credit: NIAID

SMi presents Superbugs & Superdrugs 2019The World Health Organisation is set to speak and present at this year’s Superbugs & Superdrugs Conference, taking place in London, UK on 18 – 19 March 2019.

As the worldwide danger of antimicrobial resistance remains a threat, the scientific community continues to inspire the global commitment to tackling multidrug-resistance.

Aiding this is SMi’s 21st Annual Superbugs & Superdrugs conference, which will gather international leaders from pharmaceutical companies, academia and the wider scientific community together with regulatory agencies and public-private partnerships to address the challenges and potential solutions to antibiotic resistance.

SMi is delighted to welcome a new speaker to this year’s line-up: Dr Peter Beyer, Senior Advisor at the World Health Organisation (WHO), who will provide valuable insights into how they are combating antibiotic resistance.

Dr Beyer will be sharing his vast knowledge and expertise on “The drugs don’t work: WHO’s role in advancing new antibiotics”:

  • Assessing the clinical and pre-clinical antibiotic development pipeline
  • Developing target product profiles for priority pathogens
  • The Global Antibiotic R&D Partnership (GARDP)
  • How to mobilize private investors for antibiotic drug development

Dr Beyer, a trained lawyer, is currently a Senior Advisor at the World Health Organization, where he leads a dynamic team working on antimicrobial resistance, public health, trade and intellectual property. He is responsible for the growth of a global development and stewardship framework for antimicrobial resistance, also enhancing new innovative funding mechanisms for R&D.

Dr Beyer was instrumental in creating the Global Antibiotic R&D Partnership (GARDP) which he will be discussing in further detail in his presentation, as well as the trilateral collaboration among the World Intellectual Property, the World Trade Organization and the World Health Organisation.

This year’s two-day event promises to explore the scientific, regulatory and economic challenges required to combat anti-microbial resistance, specifically focusing on antimicrobial treatment and research development, latest updates on antifungal agents, and much more.

Delegates will also have the opportunity to hear from the biggest names in Pharma, including the Wellcome Trust, F2G, Summit Therapeutics, Meiji Seika Pharma, Akthelia Pharmaceuticals, Centauri Therapeutics, and many more.

Download the brochure on the event website to see the two-day agenda and speaker line-up at http://www.superbugssuperdrugs.com/gbdpr.

Book your place before 14th December to save £200.

Global Biodefense is an official media partner of Superbugs & Superdrugs 2019.

Tags: Events

Related Posts

Novel Antibiotic Shows Success in Treatment of Plague and Melioidosis
Antimicrobial Resistance

Novel Antibiotic Shows Success in Treatment of Plague and Melioidosis

February 17, 2022
MIT Researchers Make Progress on Antibiotic Resistance Under DTRA-JSTO Research Program
Antimicrobial Resistance

MIT Researchers Make Progress on Antibiotic Resistance Under DTRA-JSTO Research Program

October 12, 2021
Long Term Care Outbreak Strike Teams, Increased Laboratory Capacity Part of $2.1 Billion CDC Effort to Enhance Infection Control
Antimicrobial Resistance

Long Term Care Outbreak Strike Teams, Increased Laboratory Capacity Part of $2.1 Billion CDC Effort to Enhance Infection Control

October 2, 2021
Is it a Bacterial or Viral Infection? Novel MeMed Rapid Test Receives FDA Clearance
Antimicrobial Resistance

Is it a Bacterial or Viral Infection? Novel MeMed Rapid Test Receives FDA Clearance

September 24, 2021
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC